Well Referenced

Tag: Non-Small Cell Lung Cancer

Lunasin sensitivity in non-small cell lung cancer cells is linked to suppression of integrin signaling and changes in histone acetylation

This 2014 study investigates the differential sensitivity of non-small cell lung cancer (NSCLC) cell lines to lunasin, a soy-derived peptide with anticancer properties. The research compares lunasin-sensitive H661 cells to resistant H1299 cells, revealing that lunasin internalization is higher in H661 cells. Lunasin interacts with integrins containing αv, α5, β1,

Read More »
June 26, 2025 No Comments

Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study

This 2013 randomized phase II study evaluated the efficacy and safety of adding mistletoe extract (Iscador) to carboplatin-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). The study found that patients receiving mistletoe extract experienced improved quality of life, including better emotional and functional well-being, compared to those receiving

Read More »
June 26, 2025 No Comments

Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis

This multicenter observational study evaluated the impact of adding Viscum album L. (European mistletoe) extract to standard chemotherapy in 158 patients with stage IV non-small cell lung cancer (NSCLC). Patients were divided into two groups: 108 received chemotherapy alone, while 50 received chemotherapy plus Viscum album L. The median overall

Read More »
June 26, 2025 No Comments

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

This 2023 observational study (Radiation Oncology, PMID: 36879290) evaluated 112 lung cancer patients, primarily with non-small-cell lung cancer (median age 70), to assess the impact of adjunctive Viscum album L. (mistletoe) therapy on quality of life (QoL) during standard treatments, including radiation. Over 12 months, patients receiving radiation plus VA

Read More »
June 26, 2025 No Comments

Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherap

This 2018 multicenter observational study (PLoS ONE, PMID: 30148853) assessed the impact of adding Viscum album L. (mistletoe extract) to standard chemotherapy in 158 patients with stage IV non-small cell lung cancer (NSCLC). Patients who received mistletoe alongside chemotherapy had significantly improved median overall survival (17.0 vs. 8.0 months, p=0.007)

Read More »
June 26, 2025 No Comments

α-Lipoic acid inhibits human lung cancer cell proliferation through Grb2-mediated EGFR downregulation

The study titled “α-Lipoic acid inhibits human lung cancer cell proliferation through Grb2-mediated EGFR downregulation” (Biochem Biophys Res Commun, 2017, PMID: 28993193) is an in vitro/animal study investigating the effects of α-lipoic acid (α-LA) on non-small cell lung cancer (NSCLC) cells. The findings indicate that α-LA suppresses NSCLC cell proliferation

Read More »
June 26, 2025 No Comments